NCT07560982Recruiting
Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure
Evaluating Adherence to Guideline- Directed Medical Therapy Using the Four-Pillar Strategy in Patients With Advanced Heart Failure: the Advanced Heart Failure Unified Board (Ad-HUB) Study
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
A Prospective Observational, Multi-Center, Real-World Pharmacological Study Evaluating Adherence to Guideline-Directed Medical Therapy Using the Four-Pillar Strategy in Patients with Advanced Heart Failure
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 24 Apr 2026
- Start date
- 8 May 2026
- Primary completion date
- 1 Jul 2031
- Lead sponsor
- Università Vita-Salute San Raffaele
- Diseases
- Heart failure
- NCT number
- NCT07560982
What you commit to
- Study type: Observational
- Planned participants: 300
- From 8 May 2026 to the primary completion date, 1 Jul 2031
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Good response to optimized conventional guideline-directed medical therapy
Other illness
- Mild or absent symptoms (New York Heart Association class I-II)
- Extreme frailty or severe non-reversible disability, or psychiatric or cognitive disorders preventing adherence to follow-up
Lab values
- Left ventricular ejection fraction \> 35%
Age
- Age ≤ 18 years or ≥ 75 years
Other
- Pregnant or breastfeeding women
Who the study is looking for
- Age \> 18 and \< 75 years
- Heart failure with left ventricular ejection fraction ≤ 35%
- Persistent symptoms of heart failure, New York Heart Association class III or IV
- Requirement for high-dose diuretic therapy, specifically Furosemide \> 50 mg/day orally as per routine clinical practice
- At least one of the following additional indicators of severity or refractoriness:
- need for progressive escalation of diuretics,
- intolerance to optimized medical therapy,
- persistence of symptoms despite advanced treatments such as (but not limited to) cardiac resynchronization therapy (CRT-D)and/or MitraClip
- Ability and willingness to provide written informed consent for participation and for the processing of clinical data for research purposes
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST Ospedale Papa Giovanni XXIII Coordinator of this site? Confirm its status | Bergamo | Italy | Not yet recruiting |
| IRCCS Ospedale San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.